Peritonitis Activates Transcription of the Human Prolactin Locus in Myeloid Cells in a Humanized Transgenic Rat Model
Lipopolysaccharides
0301 basic medicine
CD11b Antigen
Neutrophils
Reverse Transcriptase Polymerase Chain Reaction
Macrophages
Gene Expression
Bone Marrow Cells
Peritonitis
Regulatory Sequences, Nucleic Acid
Monocytes
Prolactin
Rats
3. Good health
03 medical and health sciences
Microscopy, Fluorescence
Thioglycolates
Animals
Humans
Myeloid Cells
Rats, Transgenic
Luciferases
Cells, Cultured
DOI:
10.1210/en.2011-1926
Publication Date:
2012-04-12T04:33:57Z
AUTHORS (13)
ABSTRACT
Prolactin (PRL) is mainly expressed in the pituitary in rodents, whereas in humans, expression is observed in many extrapituitary sites, including lymphocytes. Due to the lack of adequate experimental models, the function of locally produced PRL in the immune system is largely unknown. Using transgenic rats that express luciferase under the control of extensive human PRL regulatory regions, we characterized immune cell responses to thioglycollate (TG)-induced peritonitis. Resident populations of myeloid cells in the peritoneal cavity of untreated rats expressed barely detectable levels of luciferase. In contrast, during TG-induced peritonitis, cell-specific expression in both neutrophils and monocytes/macrophages in peritoneal exudates increased dramatically. Elevated luciferase expression was also detectable in peripheral blood and bone marrow CD11b+ cells. Ex vivo stimulation of primary myeloid cells showed activation of the human extrapituitary promoter by TNF-α, lipopolysaccharide, or TG. These findings were confirmed in human peripheral blood monocytes, showing that the transgenic rat provided a faithful model for the human gene. Thus, the resolution of an inflammatory response is associated with dramatic activation of the PRL gene promoter in the myeloid lineage.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....